secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001104659-23-039267
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics reports Q4 2022 net loss $11.9M; GSBR-1290 Phase 1b dosing complete
--------------------------------------------------------------------------------

- Completed dosing of GSBR-1290 Phase 1b in healthy overweight volunteers; topline data from Phase 1b and Phase 2a expected 2H 2023.
- Completed $185.3M upsized IPO in Feb 2023; net proceeds ~$166.7M; cash position $249.4M as of Feb 28, 2023.
- Cash, cash equivalents and marketable securities $90.8M at Dec 31, 2022; expects to fund operations through end of 2025.
- Net loss $11.9M Q4 2022 vs $13.4M Q4 2021; full year net loss $51.3M vs $38.0M in 2021.
- R&D expenses $8.4M Q4 2022, $36.2M full year; G&A $4.6M Q4, $16.4M full year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465923039267/0001104659-23-039267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465923039267/tm2310702d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-039267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer